iRadimed (NASDAQ:IRMD) Issues Q3 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) issued an update on its third quarter 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.540-0.590 for the period, compared to the consensus earnings per share estimate of 0.530. The company issued revenue guidance of $23.0 million-$24.5 million, compared to the consensus revenue estimate of $23.7 million. iRadimed also updated its FY 2026 guidance to 2.090-2.240 EPS.

iRadimed Stock Performance

iRadimed stock opened at $95.21 on Friday. The company has a 50 day moving average price of $94.56 and a 200-day moving average price of $95.73. iRadimed has a fifty-two week low of $57.83 and a fifty-two week high of $107.90. The company has a market capitalization of $1.22 billion, a PE ratio of 52.03 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts forecast that iRadimed will post 1.52 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Weiss Ratings cut iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $120.00.

Insider Buying and Selling at iRadimed

In related news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $87.51, for a total value of $437,550.00. Following the completion of the transaction, the chief executive officer owned 2,175,000 shares of the company’s stock, valued at approximately $190,334,250. This represents a 0.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 21,250 shares of company stock valued at $1,836,403. 34.60% of the stock is owned by insiders.

Institutional Trading of iRadimed

Hedge funds have recently bought and sold shares of the business. Quarry LP purchased a new position in iRadimed during the third quarter worth approximately $40,000. Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the period. Virtus Advisers LLC acquired a new stake in iRadimed in the 3rd quarter valued at approximately $117,000. Aquatic Capital Management LLC raised its holdings in shares of iRadimed by 210,400.0% in the 3rd quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock valued at $150,000 after buying an additional 2,104 shares during the period. Finally, Quantbot Technologies LP acquired a new position in iRadimed in the 3rd quarter valued at about $164,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.